Early Termination No Longer Means Failure. It Means the Trial Was Working.
Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...
When a Failed Primary Endpoint Teaches More Than a Win: What CARDIOTTRansform’s Secondary Analysis Reveals About Stratification in Complex Trials
CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background stabilizers is reshaping...
Psychiatry’s Stratification Crisis: How Biomarkers Are Finally Breaking the DSM’s Grip on Trial Design
Precision psychiatry biomarkers are reshaping CNS trial stratification — here's what the shift from symptom-based DSM criteria to biotype-driven...
AI Antibody Design Just Got Its First Honest Report Card — And the Grade Is Complicated
A blinded 29-org benchmark in Nature Biotechnology tested 511 AI-designed antibodies against experimental data. No single algorithm won. Here's...
The AI Validation Gap: Decision Support Tools Are Outrunning Their Own Evidence
AI clinical trial decision support is a $1.35B market growing at 12.5% annually—but FDA's draft ML guidance and real-world...
The B-Cell Depletion Arms Race in CNS Autoimmune Trials Has a New Front-Runner — And It Rewrites the Regulatory Playbook
Obinutuzumab β's Phase 3 trial shows 93.1% relapse risk reduction in AQP4+ NMOSD, forcing a rethink of how rare...
The PTSD Nightmare Drug No One Expected: What Dronabinol’s RCT Tells Us About CNS Trial Design
A dronabinol RCT in Nature Medicine just outperformed prazosin's VA trial with 170+ PTSD patients. Here's what the trial...
Routine Health Data Is Outperforming Trial Data for AI Training. The FDA Hasn’t Caught Up.
Nature Medicine finds neuroimaging AI trained on routine health system data beats curated trial datasets. FDA's RWE framework for...
The Oral Revolution in Inflammatory Skin Disease: What Povorcitinib’s Phase 3 Design Reveals About the Next Wave of Dermatology Trials
Incyte's STOP-HS1/2 trials (1,227 patients) show how JAK1-selective design and rigorous RCT methodology are reshaping dermatology's clinical trial landscape.
AI-Designed Drugs Are Reaching Human Trials. Now Comes the Hard Part.
Healx's HLX-4310 Phase 1/2 trial in osteosarcoma shows AI drug discovery maturing—but adaptive dose-escalation in adolescent oncology exposes trial...